Top of the morning to you, and a fine one it is. A spot of snow has come and gone, leaving the Pharmalot campus a bit soggy, but things have settled down, especially now that the short people have departed for the day and the official mascot has settled in for a lengthy snooze. As for us, we are, once again, brewing cups of stimulation — we are sticking with hot buttered rum, for those tracking such things — and digging in for another busy session. On that note, here are some items of interest. Hope you have a smashing day and do stay in touch …

Pfizer (PFE) disclosed an increase in pulmonary embolisms and deaths among rheumatoid arthritis patients receiving a twice-daily 10 mg dose of its Xeljanz pill in a post-marketing cardiovascular safety trial. The drug maker is moving study patients to the twice-daily 5 mg dose that is already approved. The move suggests “there is still growing evidence that the class as a whole may be associated with these liabilities,” wrote Leerink analyst Geoffrey Porges. Xeljanz generated nearly $1.8 billion in 2018 sales. The Food and Drug Administration is also conducting a review.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy